Glycomine, Inc.

Eli Lilly's Zepbound Demonstrates Superior Weight Loss Compared to Novo Nordisk's Wegovy in Head-to-Head Trial

6 months ago

• Eli Lilly's Zepbound (tirzepatide) led to a 20.2% average weight loss, significantly outperforming Wegovy (semaglutide) at 13.7% in a 72-week clinical trial. • The SURMOUNT-5 trial included overweight or obese adults without diabetes, showing Zepbound users experienced 47% more relative weight loss than Wegovy users. • Zepbound, a dual GIP and GLP-1 receptor agonist, helped 31.6% of participants achieve at least 25% body weight loss, compared to 16.1% with Wegovy. • The study's findings may influence treatment choices, with Zepbound potentially becoming a preferred option for greater weight loss outcomes, pending further data on tolerability.

FDA Grants Fast Track Designation to Glycomine's GLM101 for PMM2-CDG Treatment

8 months ago

• The FDA has granted Fast Track designation to Glycomine's GLM101, a mannose-1-phosphate replacement therapy, for treating phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG). • GLM101 is currently in a Phase 2 clinical study involving adult and adolescent patients, with plans to expand enrollment to pediatric patients aged two years and older. • Initial data from the Phase 2 study suggests promising clinical benefits with GLM101, showing good tolerability and only mild to moderate adverse events reported to date. • Fast Track designation will allow for more frequent interactions with the FDA, potentially accelerating the approval process for GLM101, addressing a significant unmet need.